In hopes of avoiding the expense, uncertainty, and complexity of the IPO process, an increasing number of companies are foregoing the IPO route and using alternative means to the public markets including reverse mergers, Form-10 self-filings, and variations of each. Hear from experienced professionals who have traveled these new routes discuss lessons learned, deal structures, and how recent legislation like the JOBS Act could affect public exits.
William Hicks, Member, Mintz Levin
Charles Crain, Manager, Policy & Research, BIO
Michelle Dipp, MD, PhD, Chief Executive Officer & Co-Founder, OvaScience
Daniel B. Dubin, MD, Vice Chairman, Chief Knowledge Officer & Founder of MEDACorp, Leerink Swann
Peter Kolchinsky, PhD, Managing Partner, RA Capital